Moderna, Inc. — Director's Dealing 2020

Dec 22, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-12-21

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-21	Common Stock	M	10000	$20.93	Acquired	10000	Direct
2020-12-21	Common Stock	M	2339	$12.21	Acquired	12339	Direct
2020-12-21	Common Stock	M	4790	$19.15	Acquired	17129	Direct
2020-12-21	Common Stock	S	601	$138.10	Disposed	16528	Direct
2020-12-21	Common Stock	S	3035	$140.11	Disposed	13493	Direct
2020-12-21	Common Stock	S	2876	$140.83	Disposed	10617	Direct
2020-12-21	Common Stock	S	1020	$142.03	Disposed	9597	Direct
2020-12-21	Common Stock	S	3415	$143.25	Disposed	6182	Direct
2020-12-21	Common Stock	S	3300	$144.28	Disposed	2882	Direct
2020-12-21	Common Stock	S	2382	$145.23	Disposed	500	Direct
2020-12-21	Common Stock	S	500	$146.19	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-21	Stock Option (Right to Buy)	$20.93	M	10000	Disposed	2029-03-08	Common Stock (10000)	Direct
2020-12-21	Stock Option (Right to Buy)	$12.21	M	2339	Disposed	2027-10-03	Common Stock (2339)	Direct
2020-12-21	Stock Option (Right to Buy)	$19.15	M	4790	Disposed	2026-08-10	Common Stock (4790)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $137.93 to $138.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $139.40 to $140.40. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $140.41 to $141.40. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $141.57 to $142.52. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $142.70 to $143.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.71 to $144.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $144.77 to $145.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $146.10 to $146.33. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F10: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).

F11: This option is fully vested and exercisable.